ONCT News and Press, Oncternal Therapeutics Inc. From 04/09/21

Provention Bio (PRVB) -38% after gives update on teplizumab BLA, FDA feedback.Virpax Pharmaceuticals (VRPX) -18%.Chemomab Therapeutics (CMMB) -17%.Iterum Therapeutics (ITRM) -15% after receiving notice from FDA on its NDA drug application for sulopenem etzadroxil/probenecid for...

Shares of clinical-stage oncology company Oncternal Therapeutics (NASDAQ: ONCT) are soaring through the roof on Wednesday thanks to bullish commentary from a Wall Street analyst. The biotech stock was up by 10.5% as of 3:41 p.m. EDT after climbing by as much as 21.8% earlier in the ...

Oppenheimer has initiated shares of Oncternal Therapeutics (ONCT) with an outperform rating.Analyst Hartaj Singh has a $14 price target on shares.Given yesterday's closing price, that represents upside of ~62%.He sees promise in shares because of a favorable risk/benefit profile of its l...

Today pre-market analyst action includes downgrades on Fibrogen and ACADIA due to recent FDA decisions on companies’ new drug applications.Fibrogen slips as analysts weigh in on safety updateFibrogen (FGEN) shares plunged in the post-market yesterday in reaction to clarification m...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

Oncternal Therapeutics is one of the few companies with clinical assets targeting ROR-1. Recent M&As for two ROR-1 companies by Merck and Boehringer Ingelheim have set a market value around $1B-$2B. With upcoming clinical catalysts for their lead drug candidate, Oncternal is a...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q4 2020 Earnings Call Mar 11, 2021 , 5:00 p.m. ET Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call Transcript

Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Conference Call March 11, 2021, 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President & Chief Executive Officer Edwina Baskin-Bey - Acting Chief Medical Officer Conference Call Participant...

Oncternal Therapeutics (ONCT): Q4 GAAP EPS of -$0.09 beats by $0.09.Revenue of $1.59M (+114.9% Y/Y) beats by $1M.As of December 31, 2020, we had $116.7 million in cash and cash equivalents. We believe these funds will be sufficient to fund our operations into 2023.Shares +2.83% AH.Press Relea...

Interim Phase 1/2 results for cirmtuzumab with ibrutinib in MCL presented at ASH in December 2020 compare favorably to historical single-agent ibrutinib data (47% CR vs. 20% CR historical single-agent ibrutinib) Accelerating development of ROR1-targeting CAR-T cell therapies ...